A detailed history of Mariner, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 34,683 shares of TGTX stock, worth $1.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,683
Previous 25,150 37.9%
Holding current value
$1.19 Million
Previous $447,000 81.43%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$17.21 - $25.28 $164,062 - $240,994
9,533 Added 37.9%
34,683 $811,000
Q2 2024

Aug 13, 2024

BUY
$13.32 - $19.19 $3,996 - $5,757
300 Added 1.21%
25,150 $447,000
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $165,998 - $467,428
24,850 New
24,850 $424,000
Q1 2023

May 12, 2023

BUY
$10.23 - $19.34 $15,345 - $29,010
1,500 Added 7.65%
21,100 $317,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $11.83 $98,196 - $231,868
19,600 New
19,600 $232,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.